August 10, 2018

Dolev Rafaeli
Chief Executive Officer
STRATA Skin Sciences, Inc.
100 Lakeside Drive, Suite 100
Horsham, Pennsylvania 19044

       Re: STRATA Skin Sciences, Inc.
           Registration Statement on Form S-3
           Filed July 23, 2018
           File No. 333-226296

Dear Dr. Rafaeli:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form S-3

Prospectus Cover, page 1

1.     We note that you are registering the resale of more shares of common
stock than you say
       were issued in the private placement. Please clarify the basis on which
you may register
       these additional shares. Also, as applicable, revise your disclosure on
page 22 to indicate
       which selling shareholders are offering those additional shares.
 Dolev Rafaeli
STRATA Skin Sciences, Inc.
August 10, 2018
Page 2
Registration Statement, page 1

2.    Given the nature and size of the transaction being registered, tell us
your basis for
      determining that the transaction is appropriately characterized as a
transaction that is
      eligible to be made on a shelf basis under Rule 415(a)(1)(i).
Selling Securityholders, page 22

3.    Please tell us why the number of shares offered by each selling
securityholder differs from
      the number of shares sold to each selling securityholder in the private
placement as
      disclosed in your Form 8-K filed May 29, 2018.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

      Please contact Caleb French at 202-551-6947 or Geoff Kruczek, Senior
Attorney, at 202-
551-3641 with any questions.



                                                             Sincerely,
FirstName LastNameDolev Rafaeli
                                                             Division of
Corporation Finance
Comapany NameSTRATA Skin Sciences, Inc.
                                                             Office of
Electronics and Machinery
August 10, 2018 Page 2
cc:       Kenneth R. Koch, Esq.
FirstName LastName